Health consumption and costs reduction in patients with ankylosing spondylitis (AS) treated with etanercept (ETA) for 2 years.

被引：0
|
作者：
Benhamou, Mathilde
Kolta, Sami
Briot, Karine
Roux, Christian
Dougados, Maxime
Fautrel, Bruno
机构：
[1] Univ Paris 05, Cochin Hosp, Dept Rheumatol, Paris, France
[2] Univ Paris 06, Pitie Salpetriere Hosp, Dept Rheumatol, Paris, France
来源：
ARTHRITIS AND RHEUMATISM | 2006年 / 54卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S718 / S719
页数：2
相关论文
共 50 条
  • [41] Dose Reduction of Tumor Necrosis Factor Inhibitor and its Effect on Medical Costs for Patients with Ankylosing Spondylitis
    Bon San Koo
    Yu-Cheol Lim
    Min-Young Lee
    Ja-Young Jeon
    Hyun-Jeong Yoo
    In-Sun Oh
    Ju-Young Shin
    Tae-Hwan Kim
    Rheumatology and Therapy, 2021, 8 : 347 - 359
  • [42] Dose Reduction of Tumor Necrosis Factor Inhibitor and its Effect on Medical Costs for Patients with Ankylosing Spondylitis
    Koo, Bon San
    Lim, Yu-Cheol
    Lee, Min-Young
    Jeon, Ja-Young
    Yoo, Hyun-Jeong
    Oh, In-Sun
    Shin, Ju-Young
    Kim, Tae-Hwan
    RHEUMATOLOGY AND THERAPY, 2021, 8 (01) : 347 - 359
  • [43] Spinal radiographic progression over 2years in ankylosing spondylitis patients treated with secukinumab: a historical cohort comparison
    Braun, J.
    Haibel, H.
    de Hooge, M.
    Landewe, R.
    Rudwaleit, M.
    Fox, T.
    Readie, A.
    Richards, H. B.
    Porter, B.
    Martin, R.
    Poddubnyy, D.
    Sieper, J.
    van der Heijde, D.
    ARTHRITIS RESEARCH & THERAPY, 2019, 21 (1)
  • [44] Long-term outcome of patients with active ankylosing spondylitis with etanercept-sustained efficacy and safety after seven years
    Baraliakos, Xenofon
    Haibel, Hildrun
    Fritz, Claudia
    Listing, Joachim
    Heldmann, Frank
    Braun, Juergen
    Sieper, Joachim
    ARTHRITIS RESEARCH & THERAPY, 2013, 15 (03)
  • [45] Rates of cardiovascular events in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis treated with etanercept or placebo in clinical trials.
    Bathon, J.
    Fleischmann, R.
    Peloso, P.
    Chon, Y.
    Hooper, M.
    Lin, S-L
    ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S188 - S188
  • [46] Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept
    Braun, J
    Baraliakos, X
    Listing, J
    Sieper, J
    ARTHRITIS AND RHEUMATISM, 2005, 52 (08): : 2447 - 2451
  • [47] Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: Clinical data supported by magnetic resonance imaging
    Baraliakos, X.
    Rudwaleit, M.
    Listing, J.
    Sieper, J.
    Braun, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : A44 - A44
  • [48] Long-term outcome of patients with active ankylosing spondylitis with etanercept-sustained efficacy and safety after seven years
    Xenofon Baraliakos
    Hildrun Haibel
    Claudia Fritz
    Joachim Listing
    Frank Heldmann
    Juergen Braun
    Joachim Sieper
    Arthritis Research & Therapy, 15
  • [49] Possible predictors for relapse from etanercept discontinuation in ankylosing spondylitis patients in remission: a three years’ following-up study
    Minjing Zhao
    Pingping Zhang
    Linkai Fang
    Zhongxing Luo
    Jieruo Gu
    Zhiming Lin
    Clinical Rheumatology, 2018, 37 : 87 - 92
  • [50] Sustained efficacy and safety, including patient-reported outcomes, with etanercept treatment over 5 years in patients with ankylosing spondylitis
    Martin-Mola, E.
    Sieper, J.
    Leirisalo-Repo, M.
    Dijkmans, B. A. C.
    Vlahos, B.
    Pedersen, R.
    Koenig, A. S.
    Freundlich, B.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2010, 28 (02) : 238 - 245
12345